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Abstract
Background
Non-vitamin K antagonist oral anticoagulants (NOAC) are equally or potentially superior in
terms of effectiveness in the prevention of ischemic stroke and carry a lower associated risk
of intracranial hemorrhage compared to Vitamin K antagonists. Nevertheless, ischemic
strokes also occur in patients who are being treated with NOAC. In those particular patients,
knowledge about the underlying stroke etiology, clinical presentation, acute management,
and complication rates is scarce.
Objective
Systematic literature review to provide a comprehensive clinical overview in terms of pre-
sentation, laboratory, imaging parameters and outcomes of patients suffering from acute
cerebral ischemic events (i.e. TIA and acute ischemic stroke) while on treatment with a
NOAC. Only if available, comparison to VKA is presented which was not the primary focus
of this analysis.
Data sources
PubMed/MEDLINE, Scopus and EMBASE from January 1, 2006, to November 20, 2018.
Study eligibility criteria
52 studies providing detailed information on a total of 12247 patients were included. We
excluded case reports and case series with less than five patients.
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Study appraisal and synthesis method
We systematically assessed study quality using a bias tool and pooled consistent data.
Results
Existing data indicates milder stroke severity and smaller infarct size of acute ischemic
stroke on treatment with NOAC compared to stroke occurrence on Vitamin K antagonists
(VKA). Established risk factors for ischemic events also play a role in stroke while on
NOACs, albeit the underlying etiology remains poorly understood. Intravenous thrombolysis
and endovascular therapy seem to be safe and effective, but patient selection for recanali-
zation therapies is challenging.
Limitations
Limited quality of published data, duplicate cases, statistical issues of data pooling, possible
incomplete retrieval of identified research and reporting bias might have limited our findings.
Conclusions
Acute ischemic events despite treatment with NOAC therapy are insufficiently investigated.
Systematic review registration number
PROSPERO: CRD42018074853.
Introduction
Rationale
The introduction of rivaroxaban in 2008 and the subsequent addition of three more non-vita-
min K antagonist oral anticoagulants (NOAC) had an enormous impact on the primary and
secondary prevention of acute ischemic stroke (AIS) in the setting of nonvalvular atrial fibrilla-
tion (AF). Most guidelines now recommend NOAC over vitamin K antagonists (VKA) with a
class I recommendation level [1–4]. The net clinical benefit arises mainly from a reduced risk
of intracerebral hemorrhage (ICH) with NOAC treatment, whereas the prevention of AIS or
TIA, which are later in this review referred to as acute ischemic events (AIE), is equal or better
compared to VKA treatment. Nevertheless, 1–2% of patients per year suffer from an AIE while
on NOAC treatment [5]. The knowledge about stroke subtype, vessel occlusion location, pat-
tern of cerebral infarction, complications and therapy strategies in those patients is scarce.
Identifying factors that are associated with AIE that occur while on NOAC treatment may
improve individualized treatment decisions. Furthermore, it is important to analyze the rea-
sons for NOAC failure in real-life data, because randomized-controlled trials represent a
highly selective patient population. For example an additional indication for anticoagulation,
chronic non-steroidal anti-inflammatory drug therapy, severe chronic renal insufficiency, ane-
mia, unreliability or short life expectancy (e.g. malignancy) were exclusion criteria in the piv-
otal phase III trials, but are likely to be present in NOAC real-life patients [6–9].
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Objectives
We aimed to provide a comprehensive clinical overview (clinical presentation, laboratory,
imaging parameters and outcomes) of AIE in patients on NOAC treatment by performing a
systematic review of the current literature. Only if available, comparison to VKA is presented
which was not the primary focus of this analysis.
Methods
Protocol and registration
The study protocol has been published prior to performing the study (PROSPERO:
CRD42018074853).
Eligibility criteria
Eligible studies included all age groups and all ethnic groups with given demographic, clinical,
laboratory or imaging information on NOAC patients in the setting of AIE. We included all
evaluative methodologies. Since the first NOAC, rivaroxaban, entered the market in 2008, we
only considered publications beyond January 1st, 2006 for analysis. We excluded studies with
no specific characterization of patients who suffered an AIE while taking NOAC. We excluded
case reports and case series with less than five patients.
Information sources
Data for this review was identified via a search on MEDLINE, PubMed, Scopus and Embase
and references from relevant articles using the search terms "DOAC" OR “NOAC” OR "antic-
oagulation", and "ischemic stroke" or “TIA”. Only articles published in English, French, Span-
ish and German between January 1st, 2006 and November 20th, 2018 were included.
Search
This is the detailed search strategy used for PubMed: ("noacs"[All Fields] OR "noac"[All Fields]
OR "non-vitamin k oral anticoagulants"[All Fields] OR "non-vka oral anticoagulant"[All
Fields] OR "doacs"[All Fields] OR "doac"[All Fields] OR "direct oral anticoagulant"[All Fields]
OR "direct oral anticoagulants"[All Fields] OR "factor xa inhibitor"[All Fields] OR "direct
thrombin inhibitor"[All Fields] OR "dabigatran"[All Fields] OR "pradaxa"[All Fields] OR "riv-
aroxaban"[All Fields] OR "xarelto"[All Fields] OR "apixaban"[All Fields] OR "eliquis"[All
Fields] OR "edoxaban"[All Fields] OR "lixiana"[All Fields] OR "savaysa"[All Fields]) AND
("ischemic stroke"[All Fields] OR "tia"[All Fields] OR "transient ischemic attack"[All Fields])
AND (("2006/01/01"[PDAT]: "2018/11/20"[PDAT]) AND "humans"[MeSH Terms] AND
(German[lang] OR English[lang] OR French[lang] OR Spanish[lang])).
Study selection
Citations were uploaded into the covidence online review tool. Their relevance was assessed
against the predetermined inclusion and exclusion criteria by TRM and SF, who indepen-
dently screened all titles and abstracts. Forward and backward reference searching comple-
mented the database searches. Full-text manuscripts were obtained for all studies entering the
review. Any uncertainties about including a specific manuscript in the review were resolved by
consensus.
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Data collection process
Data was extracted onto an Excel spreadsheet by SF and reviewed by TRM.
Data items
Data items included number of patients, age, sex, race, vascular risk factors, type of NOAC
and dose, concomitant medication, clinical features of the AIE such as stroke severity, drug
levels, renal function, coagulation parameters, imaging findings, stroke etiology, acute man-
agement and outcome parameters (functional outcome, mortality).
Risk of bias in individual and across studies
We compared data items, outcomes, design strengths and weaknesses across the studies. For
each study, the risk of bias was thoroughly assessed at the study level using a modified National
Heart, Lung, and Blood Institute (NHLBI) bias tool, and this information was incorporated
when interpretation of data was given in the synthesis.
Summary measures
The principal summary measures were the clinical characteristics of patients using a NOAC in
the setting of AIE.
Synthesis of results
If available and consistent throughout the studies, the pooled mean weighted corresponding to
the sample size is presented. Data items given by median and interquartile range were con-
verted assuming gaussian distribution as described earlier [10]. Until stated otherwise, the
comparison to VKA patients is provided within each individual study.
Additional analyses
No additional analyses were performed.
Study selection
The database searches and citation tracking yielded 1309 hits, of which 1025 records were
screened as potentially relevant after removing duplicates (Fig 1). Reasons for excluding rele-
vant publications were mainly due to the lack of specific data items on individual patients. In
total, 52 publications including 12247 patients met the inclusion criteria and were included in
the analysis (1 substudy of a randomized interventional trial, 1 prospective non-randomized
interventional trial, 1 nested case-control study, 28 non-randomized observational studies; 18
case series, 2 diagnostic studies, 1 substudy of an observational register).
Study characteristics
The extracted data of the included publications is shown in S1 Table.
Risk of bias within and across studies
We used 14 quality items to assess bias using a modified NHLBI bias tool [11]. We defined
study quality as low when the sum of the positive quality items was less than six and moderate
when it was between six and nine. Overall, the risk of bias was considerable across the studies.
20 studies had moderate quality, and 32 studies had low quality. Retrospective design, small
sample size, publication bias, selective reporting and the slanted choice of a particular NOAC
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therapy versus VKA therapy contributed to bias. The detailed bias assessment of each individ-
ual study using the modified NHLBI bias tool is available in the S2 Table.
Fig 1. PRISMA flow diagram. Mainly studies were excluded because they only reported incidence rates of ischemic stroke or TIA patients without further clinical
information on those patients.
https://doi.org/10.1371/journal.pone.0213379.g001
Ischemic stroke and TIA in patients taking novel anticoagulants - Systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0213379 March 29, 2019 5 / 18
Results
Risk factors and reasons for AIE while using a NOAC
In patients starting NOAC therapy, AIE were reported to occur more frequently during the
first three months of treatment [12,13] with a declining AIE rate thereafter. Established risk
factors such as previous AIE or an elevated CHA2DS2-VASc score were reported to predict
AIE while using a NOAC [14–16]. Renal impairment, defined as estimated glomerular filtra-
tion rate of less than 60ml/min, was also reported to be a predictor of AIS while on NOAC
therapy [17], which fits the borderline impaired pooled renal function parameters in our
cohort. Kamal et al. reported an elevated mean body mass index (BMI) in NOAC failure [18].
This is in contrast to Arihiro et al. who found a reduced BMI patients with AIE in NOAC fail-
ure [19]. The mean weighted BMI in the pooled cohort was slightly elevated.
Severity and infarction size of AIE. Overall, AIS severity while on a NOAC measured by
the National Institutes of Health Stroke Scale (NIHSS score) was mostly mild, and the outcome
was favorable compared to AIS severity while on a VKA [13,15,20–27]. The mean weighted
NIHSS score on admission in the pooled NOAC cohort was 4.6. In the biggest data set from
the Get with the Guidelines Register, stroke severity while on a NOAC was equal to stroke
severity while on a well-controlled dose of a VKA (NIHSS score 4), but stroke severity while
on a NOAC was less severe when the international normalized ratio (INR) was not within the
therapeutic range (NIHSS score 6) [28]. Opposing data was reported by Nakase et al., who
found a higher NIHSS score in AIS while on a NOAC compared to VKA [29]. In patients qual-
ifying for intravenous thrombolysis (IVT) or endovascular therapy (EVT), NIHSS score values
were overall high, but roughly equal with NOAC and VKA pretreatment respectively [30–33].
The ischemic lesion size on magnetic resonance imaging (MRI) was reported to be signifi-
cantly smaller while on a NOAC versus a VKA [23–25,29]. Also, in comparison to AIS while
on acetylsalicylic acid, the size of the infarction on apixaban was smaller while the overall
infarct rate was equal [34]. The distal middle cerebral artery territory was reported to be the
most location of embolic strokes [18].
Dosing regimen. After propensity-score matching for baseline demographic parameters
and co-morbidities, it was found that there was a significantly lower adherence rate than
expected among the twice-daily NOAC users. The suboptimal adherence to any dosing regi-
men was reported to be associated with a 50% increased hazard ratio for AIS [35].
NOAC treatment was frequently found to be interrupted before an AIE [21,36]. Further-
more, subtherapeutic dosing was reported in a relevant proportion of patients as a possible
explanation for NOAC failure [15,16,24,37,38]. For example, Sakamoto et al. found an inap-
propriately lowered dose in about 25% of patients in their cohort [15]. Nevertheless, AIE do
occur despite NOAC drug levels being well within the therapeutic range [39].
Etiology. Overall, there are conflicting results regarding stroke subtypes in patients with
AIE while on NOAC therapy. Some authors reported that cardioembolic sources, such as
intracardiac thrombus or severe congestive heart failure, might present as a frequent reason
for AIE under NOAC therapy [13,19–21]. On the other hand, other authors reported a pre-
dominantly non-cardioembolic etiology for AIS while on a NOAC, such as microvascular dis-
ease [15,40]. Other etiologies for AIS while on NOAC therapy include paraneoplastic
coagulation disorders, arterio-arterial embolism [41] and polypharmacy [16].
Coagulation testing. Routine coagulation tests in patients undergoing NOAC therapy
show strong variability and therefore cannot sufficiently predict current anticoagulant effect
[42,43]. High plasma levels may remain elevated for more than 12 hours after last intake [43].
Despite this fact, specific coagulation tests are only performed in less than half of acute stroke
patients in the emergency setting, even in experienced stroke centers [27,39].
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Reperfusion therapies in the acute setting in patients with AIS under
NOAC
IVT. In the Get With The Guidelines register, rates of IVT use were much lower in
NOAC patients compared to subtherapeutic VKA patients in the (3.3% vs. 11.7%) [28]. Also,
Purrucker et al. found NOAC treatment to be a significant barrier to IVT initiation and a
cause of an overall lower rate of IVT usage (9/159 patients; 5.7%) in patients on NOAC therapy
[44]. Suspected or proven NOAC treatment was reported to be the main reason for not admin-
istering IVT in more than half of all patients on their register. Also, an overall time delay to
treatment of 35 minutes was reported in NOAC patients compared to VKA patients [30]. In
the pooled cohort, the overall rate of IVT in most tertiary stroke centers was low (5.1%) and
time from symptom onset to IVT was almost two and a half hours. Seiffge et al. could show,
that more than half of patients on rivaroxaban could be candidates for IVT because of low
plasma levels on admission [45].
Deciding for or against IVT. In the absence of specific coagulation testing, the time of
the last NOAC dose prior to the AIS is of major importance in the decision to administer or
withhold IVT, considering also the presence or absence of drug interactions as well as renal
and hepatic function. Seiffge et al. reported that about half of their patients with an AIS had
their last dose less than 12 hours before hospital admission, whereas the other half had their
last dose between 12 and 24 hours before hospital admission [30]. Factor IIa activity assays are
the standard of care in dabigatran users with an AIS in deciding for or against IVT. However,
if not available, a thrombin time (TT) based protocol (< 38 sec) might be a reasonable alterna-
tive [46]. Seiffge et al. showed that a specific factor Xa-activity assay is useful in patients treated
with rivaroxaban with an AIE, and that the use of IVT in patients with low levels of factor Xa-
activity might be safe. Despite using specific coagulation testing, a a fast door-to-needle time
of 37 minutes was feasible [47].
Hemorrhagic complications after IVT. Two studies found no increase in acute-phase
hemorrhagic transformation compared to VKA [15,48]. In the largest register dataset available,
patients with NOAC pretreatment had the lowest unadjusted rates of life-threatening or seri-
ous systemic hemorrhage (0.4%) and of any other IVT complication (6.8%) compared to
patients with antiplatelet, VKA or no medical pretreatment. However, data on coagulation
parameters, the timing of the last NOAC intake, and whether nonspecific reversal strategies
may have been applied were not available [49].
Olivera et al. reported ICH in two of seven patients taking a NOAC and receiving IVT.
However, the definition of ICH was not clear [14]. Chen et al. reported severe bleeding events
in 2/19 patients receiving IVT in patients taking rivaroxaban with both events occurring in
patients with last drug intake <48h before IVT treatment [50]. In contrast, Seiffge et al. found
a similar rate of symptomatic ICH using the National Institute of Neurological Disorders and
Stroke (NINDS) or European Cooperative Acute Stroke Study II (ECASS-II) definition (sICH)
in NOAC patients receiving IVT [30,51,52] and no sICH when the selection of therapy was
guided by plasma levels in patients taking rivaroxaban [47]. Suzuki et al. reported no sICH at
24 hours in 71 patients receiving IVT with the study being limited by recall bias and reduced
IVT dose [53].
Idarucizumab. In the biggest case series including 55 patients, IVT after dabigatran rever-
sal was feasible with a symptom onset to needle time of 175 minutes [33]. Furthermore, its use
was effective with a mean clinical improvement seen in 82% of the patients (6.3 points differ-
ence in NIHSS) and a follow-up mRS <2 in 56% of patients. The rate of sICH (3/55, 5.5%) was
within the expected range. Other complications included one fatal thrombotic adverse
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occurring five days after the Idarucizumab/IVT infusion [54]. However, most authors reported
favourable outcome of this approach [55–57].
Endovascular therapy (EVT). A target large vessel occlusion was more often observed
when NOAC dose was incorrectly low or compliance inadequate [58]. Seiffge et al. reported
EVT without IVT in patients with high rivaroxaban plasma levels to be safe and feasible
[30,47]. Several authors reported EVT to be safe and feasible with a similar rate of sICH as
compared to patients without anticoagulation [59–63].
Outcome. Similar outcomes between AIE on NOAC or on VKA treatment were found
[24]. This was also true in patients receiving IVT [30] and EVT [14,59]. Overall, in-hospital
mortality was highest in patients not receiving antithrombotic treatment prior to the AIS
(9.3%), followed by subtherapeutic warfarin (8.8%), antiplatelet treatment only (8.1%), thera-
peutic warfarin (6.4%), and NOAC (6.3%) [28].
Management. There are no randomized trials on the therapeutic management after AIE
on NOAC. Following the AIE, switching temporarily to low molecular weight heparin was
preferred by some authors [14], whereas most authors preferred switching to another NOAC
with a different mechanism of action [40] for long-term prophylaxis. However, sometimes
restarting the same NOAC was favored—possibly due to the good outcome of AIE on dabiga-
tran and the possibility of antagonizing its effect by idarucizumab [33,54,64]. Also, a change of
VKA was reported [14].
Synthesis of results
The pooled data is shown in Table 1. Additionally, in S3 Table we provide the pooled data con-
sidering only studies of at least moderate quality, although there were no relevant differences
compared to the data of all included studies.
Additional analysis
No additional analysis was performed.
Discussion
Epidemiology
It was expected that about 1% of AIS patients will be on NOAC treatment in the future [65].
With an estimated AIE rate of 1–2% per year in patients taking a NOAC and the increasing
number of indications for NOAC use, this rate is likely to increase significantly [66] reaching
6% in 2017 in our tertiary stroke center.
Risk factors and reasons for AIE under NOAC
Information on stroke subtype distribution according to validated classifications such as the
Trial of Org 10172 in Acute Stroke Treatment (TOAST) or ASCOD in AIE under NOAC is
currently not available [67,68].
Apart from the classical etiologies, there are several potential reasons for an AIE while tak-
ing a NOAC, including non-adherence to medication, under-dosage and potential treatment
failure of NOAC with thrombus formation despite treatment.
The finding that classical vascular risk factors are associated with AIE under NOAC sug-
gests that large artery disease or small vessel disease may represent a cause of AIE in a relevant
percentage of patients [69]. However, incorporation of biomarkers associated with cardioem-
bolic etiology (Cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and D-dimer)
enhanced risk assessment for subsequent ischemic events [70]. Surprisingly, the finding that
Ischemic stroke and TIA in patients taking novel anticoagulants - Systematic review
PLOS ONE | https://doi.org/10.1371/journal.pone.0213379 March 29, 2019 8 / 18
previous AIS predicts treatment failure is in contrast to a subgroup analysis of the ROCKE-
T-AF trial [71]. Future research should address the question whether impaired renal function
Table 1. Pooled characteristics of patients suffering acute cerebral ischemic events while taking non-vitamin K antagonist oral anticoagulants (N = 12247).
Characteristic item positive item available % Weighted mean
Female sex 5594 10898 51.3
Age (years) 10989 78.6
BMI (kg/m2) 750 26.3
Medical history
Atrial fibrillation 11036 11301 97.7
Hypertension 8614 10450 82.4
Dyslipidemia/hyperlipidemia 4984 9721 51.3
Previous ischemic stroke or TIA 4465 10191 43.8
Coronary heart disease or
myocardial infarction
3438 10040 34.2
Diabetes mellitus 3456 10436 33.1
Heart failure 2013 9616 20.9
Smoker 745 9298 8.0
Peripheral vascular disease 575 8900 6.5
Carotid stenosis 415 8859 4.7
Prosthetic heart valve 142 8768 1.6
NOAC
Rivaroxaban (total) 1626 3092 52.6
Dabigatran (total) 1162 3092 37.6
Apixaban (total) 299 3092 9.7
Edoxaban (total) 5 3092 0.2
Twice daily 635 1150 55.2
Once daily 500 1150 43.5
Medication
Antihypertensive 7170 9190 78.0
Cholesterol lowering drug 5866 9587 61.2
Diabetes medication 2054 8859 23.2
Concomitant antiplatelet 333 1668 20.0
Laboratory
Serum creatinine (mg/dl) 833 0.95
Renal clearance (ml/min) 897 63.5
apTT (sec) 650 34.5
INR 9756 1.2
Blood glucose (mg/dl) 742 124.2
D-Dimer (ng/ml) 128 964.1
BNP (pg/ml) 128 198.4
Clinical features
Stroke severity (NIHSS score) 10291 4.6
Treatment
Any IVT 598 9196 6.5
Onset of symptoms to IVT (min) 402 141.9
Time since last drug intake to IVT (h) 276 10.2
BMI: body mass index, apTT: activated Partial Thromboplastin Time, INR: international normalized ratio, BNP: brain natriuretic peptide, NIHSS: National Institute of
Health Stroke Severity, IVT: intravenous thrombolysis.
https://doi.org/10.1371/journal.pone.0213379.t001
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is an independent predictor of AIE in patients taking NOAC or only if inadequate dosing is
prescribed. Importantly, it was shown, that excellent renal function was a risk factor of AIE, at
least in patients receiving Edoxaban [72].
Recurrent AIE is reported to occur more frequently in the first three months after NOAC
therapy initiation, which behooves caregivers and patients to be especially attentive to the
signs of an AIE. The elevated risk in the first weeks after the event at the same time of NOAC
initiation might explain this observation. However, it might also be possible that the increased
incidence in the first three months may be because NOACs may induce the mobilization of
preexisting thrombi. Comparison of NOAC initiation for primary and secondary prophylaxis
could clarify this phenomenon. Insufficient drug levels due to varying drug interactions have
been analyzed [73], but their relevance in the real-world setting remains unclear.
Furthermore, early termination in up to one of three NOAC patients within the first year of
treatment has been reported [74,75]. In this setting, mild cognitive dysfunction was not a risk
factor for non-adherence [76].
Severity and infarction size of AIE
The severity of an AIS while on a NOAC seems to be at least equal compared to VKA pretreat-
ment. This finding is confirmed by another study that showed an equally reduced frequency of
severe strokes in patients on therapeutic doses of a VKA as well as patients on NOAC therapy
[77]. There is insufficient data on AIS size, although preliminary data, which showed smaller
infarct volumes on MRI, was reassuring [25].
Dosing regimen
Once daily dosing seems to be associated with a slightly better adherence [78]; although its
effect in clinical practice is unclear because worse pharmacokinetics could easily balance this
benefit [79]. Because body weight and renal function might be altered in the acute event set-
ting, NOAC doses should be reviewed after about three weeks [38]. Treatment discontinuation
in about a quarter of patients at one year demands care models increasing the delivery of con-
tinuous therapy [80].
Laboratory parameters
Abnormal routine coagulation tests may provide a hint that a patient presenting with an AIE
might take a NOAC, but they do not reflect the actual coagulation status. Specific tests for the
activity of a particular NOAC should be used routinely, because they aid in the decision to
administer or withhold IVT. Prospective studies with consistent data are warranted to define
reliable recommended cut-off values for each NOAC.
Reperfusion therapies in the acute setting in patients with AIS under
NOAC
IVT. There are no randomized trials concerning IVT in the setting of an AIS under a
NOAC. Seiffge et al. estimated that IVT could be used in more than half of patients with prior
rivaroxaban treatment with about 28% of patients denied by current guidelines [30,45,81].
Recent analyses concluded that IVT is probably effective and safe in select AIS patients under-
going NOAC treatment [81–84]. However, optimal patient selection is dependent on coagula-
tion parameters that have not yet been sufficiently evaluated, and the variable selection criteria
used in available studies do not allow for a consensus [39,42,85,86]. Prospective, randomized
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studies are crucial for the creation of valid guidelines for this situation comparable to the INR
cutoff in VKA patients.
EVT. EVT also seems to be safe and effective in large vessel occlusion (LVO) in patients
undergoing NOAC therapy, but further trials are needed to confirm general safety [60,87].
Either on its own or in combination with, recanalization strategies are available for about one
out of three patients with an AIS undergoing therapy with a NOAC [47].
NOAC reversal agents. Initial reports on successful and safe IVT after idarucizumab
administration are promising, but limited experience does not allow for a final statement on
the safety of IVT after antagonization [33,84]. Additionally, it is not clear whether idarucizu-
mab/IVT should be administered in every dabigatran patient with an AIS or only if direct EVT
is not possible. No data is presently available for the recently approved reversal agent for factor
Xa inhibitors, andexanet alfa.
ICH. The incidence of ICH after an AIS with or without IVT/EVT seems to be low, but
systematic prospective trials are lacking. Furthermore, heterogeneous definitions of a symp-
tomatic ICH impair the comparability of study results.
Management. Since guidelines on the management of an AIE under NOAC therapy are
lacking, and the underlying etiology is heterogeneous, it seems to be most important to search
for potentially treatable sources of stroke, such as symptomatic atherosclerotic stenosis, para-
neoplastic syndrome, vasculitis or endocarditis. Moreover, a measurement of NOAC activity
on admission may help to identify instances of compliance-related AIE and to guide individu-
alized dosing of NOACs in the future.
When none of the listed etiologies are found, it is controversial, but many clinicians switch
to another NOAC substance [88].
Summary of evidence
AIE in patients using a NOAC are becoming a more frequent event. Contributing risk factors
as well as the etiology remain poorly understood. Stroke severity seems to be favourable or at
least equal to an AIS that occurs while on a VKA. Standardized management protocols for
diagnostic work-up and management are necessary to provide optimal and rapid stroke care.
IVT and EVT seem to be safe and effective, but patient selection for these therapies is
challenging.
Limitations
Our analysis has several limitations that limit the generalization of findings. Those include the
overall low quality of published data, statistical pooling procedures, incomplete retrieval of
identified research, reporting bias, and the small number of reports of patients suffering from
an AIE while using Apixaban and Edoxaban. Furthermore, we only report characteristics of
patients suffering AIE while taking NOAC, but we had no information on patients on NOAC
not suffering AIE which limits the explanatory power of the findings.
Conclusions
There is an unmet need for prospective trials on the diagnostic workup and treatment of an
AIE under NOAC therapy. High volume registers of patients suffering from an AIE while
undergoing NOAC therapy are already being created and will hopefully soon contribute to the
management of AIE under NOAC therapy. (RASUNOA prime, ClinicalTrials: NCT02533960;
NOACISP; ClinicalTrials: NCT02353585, ARAMIS Register, ClinicalTrials: NCT02478177).
Studies included. [12–16,18–24,26–29,31,34,37,40–42,44,46,47,49,54–56,58,59,64,77,78,
83,89–101].
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